Welcome to our dedicated page for Lifecore Biomedical SEC filings (Ticker: LFCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for Lifecore Biomedical, Inc. (NASDAQ: LFCR), a Delaware corporation based in Chaska, Minnesota that operates as a fully integrated CDMO focused on sterile injectable pharmaceuticals and injectable-grade hyaluronic acid. These regulatory documents offer detailed insight into how the company reports its operations, governance, and financial condition.
Through filings such as the annual report on Form 10-K and quarterly reports on Form 10-Q, investors can review discussions of Lifecore’s CDMO and HA manufacturing activities, risk factors, and management’s analysis of results. Current reports on Form 8-K highlight specific events, including financial results announcements, changes in independent registered public accounting firms, investor presentations used in discussions with analysts, and matters submitted to a stockholder vote at the annual meeting.
The definitive proxy statement on Form DEF 14A describes corporate governance topics such as director elections, auditor ratification, and advisory votes on executive compensation, as well as stock ownership and compensation discussion and analysis. Other filings may address compensation plans and incentive structures, including bonus plans tied to metrics like Adjusted EBITDA and total revenue, as described in the company’s disclosures.
On Stock Titan, these filings are updated from the SEC’s EDGAR system and can be paired with AI-powered summaries that help explain complex sections, highlight key changes, and clarify terminology. Users can quickly identify items related to financial performance, internal control matters, auditor changes, and stockholder voting outcomes without reading every page. For those interested in governance, accounting, or the details behind Lifecore’s CDMO and HA manufacturing business, this filings page serves as a structured entry point into the company’s official regulatory record.
Lifecore Biomedical, Inc. filed a Form S-3 shelf registration to register up to 20,456,637 shares of common stock for resale by certain selling stockholders, including 6,556,521 issued shares and 13,900,116 shares issuable upon conversion of Series A Convertible Preferred Stock. The company notes its common stock trades on the Nasdaq Global Select Market under the symbol LFCR, with a reported price of $7.87 on September 19, 2025. The Series A Convertible Preferred Stock carries a 7.5% per annum PIK dividend, an initial conversion price of $7.00 per share (adjusted to approximately $6.53 after a prior private placement) and a liquidation preference equal to the greater of the purchase price plus accrued dividends or the as-converted value. The prospectus incorporates prior SEC filings by reference. The independent auditor, BDO USA, P.C., issued an adverse opinion on the effectiveness of the company’s internal control over financial reporting as of May 25, 2025.
Lifecore Biomedical presents its definitive proxy with board nominations, governance policies, executive pay detail, legal proceedings, and auditor changes. The filing discloses nine director nominees including two Series A Preferred nominees and emphasizes a non-executive Chairperson presiding over independent director executive sessions. It describes a Code of Business Conduct, an ethics hotline, and committee independence. The company is defending a December 23, 2024 complaint by 22NW Fund alleging misrepresentations and breaches; the company moved to dismiss most claims but accrued registration delay fees. Auditor BDO reported material weaknesses in internal control for fiscal years ended May 26, 2024 and May 25, 2025; Audit Committee approved transition to KPMG for the remainder of 2025. Executive compensation changes, PSU and RSU awards, severance terms, and a strong 99.1% say-on-pay vote are disclosed.
Ryan Lake, Chief Financial Officer of Lifecore Biomedical, Inc. (LFCR), reported a transaction dated 09/03/2025 in which 22,932 shares of common stock were disposed of at $7.71 per share. The filing states these shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs). After the withholding, Mr. Lake beneficially owns 336,691 shares directly. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Lifecore Biomedical reported material weaknesses in its internal control over financial reporting, identifying deficiencies in Information and Communication, Control Activities and Monitoring. The company said the weaknesses relate to accounting and classification of non-standard transactions, inventory valuation, capitalization of interest on assets under construction, recognition of development revenue and related cost of sales, presentation of operating costs for continuing and discontinued operations, and write-offs of receivables from its former Curation Foods businesses. Management concluded that, as of May 25, 2025, these deficiencies remained aggregated as material weaknesses. The Audit Committee discussed the issues with BDO, authorized BDO to respond to KPMG inquiries, and filed BDO's letter as Exhibit 16 to the Form 8-K.
Lifecore Biomedical intends to use a presentation in discussions with investors, analysts and others and has furnished that presentation as Exhibit 99.1 to this Current Report. The company says the Presentation will be posted on its investor relations website and that the material furnished in this Item (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act nor incorporated by reference into future Securities Act filings unless expressly stated.
This disclosure is a Regulation FD furnishing of investor materials and confirms where the Presentation will be available; the report is signed by the company's Chief Financial Officer.